
Opinion|Videos|April 16, 2024
Setting Expectations + First-Line and Second-Line Treatment of Graft Versus Host Disease
A medical professional outlines the goals and challenges of communicating with his patient, emphasizing the importance of setting realistic expectations for halting disease progression and potentially achieving some degree of disease reversibility, while also exploring the roles of first-line and second-line therapies in the management of chronic graft versus host disease.
Advertisement
Episodes in this series

Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
ASCENT-07: Sacituzumab PFS Not Significant vs Chemo in HR+/HER2- BC
2
T-DXd Plus Pertuzumab Yields Favorable Benefit Over SOC in HER2+ Breast Cancer
3
Giredestrant Improves IDFS vs SOC in ER+/HER2– Early Breast Cancer
4
Aromatase Inhibitors Favored as Adjuvant ET in HR+/HER2+ Early Breast Cancer
5







































